In the manufacture of a 10–20 mg lutein/zeaxanthin ophthalmic tablet, the marigold flower extract API is incorporated into a direct-compression matrix rather than subjected to aqueous granulation, because residual moisture from wet massing accelerates the isomerization of lutein during tray or fluid-bed drying. For an extract standardized to ≥80 wt% total lutein/zeaxanthin, the API is loaded at 2.5–5.0 wt% of core tablet mass, corresponding to 12.5–25.0 mg API per 500 mg core to deliver the label claim. The direct blend consists of microcrystalline cellulose with mean particle size 98–102 µm, anhydrous dibasic calcium phosphate as a chipping-resistant diluent, croscarmellose sodium at 1.5–2.5 wt%, and magnesium stearate capped at 1.0 wt%; higher lubricant levels reduce compact tensile strength because the hydrophobic beadlet surfaces interfere with bond formation at the beadlet–cellulose interface. Blending proceeds in a 600 L V-blender at 60% load and 25 rpm for 8–12 min, with pre-dispersion of the API in a 1:3 geometric dilution with microcrystalline cellulose before addition of the disintegrant. Compression is performed on a rotary tablet press fitted with 8–10 mm concave B-tooling punches, 8–12 kN compaction force, and turret speed 25–35 rpm; lower compaction force yields capping at press startup, while higher force darkens the core due to localized shear at the punch face. Release testing is anchored to USP <711> dissolution apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl with 0.5% sodium lauryl sulfate, USP <905> uniformity of dosage units, ICH Q3D elemental impurities, and ICH Q3C residual solvents. The terminal dosage form is a film-coated ophthalmic tablet, typically 10.0 mg or 20.0 mg lutein, protected by a light-barrier PVC/PVDC/aluminum blister.

What Shifts Lutein Degradation Kinetics During Wet Granulation and Drying?

Wet granulation is used for high-dose marigold flower extract formulations when direct compression cannot accommodate the required API addition without unacceptable segregation. The degradation of lutein/zeaxanthin during aqueous processing is driven by three variables: granulation moisture, drying temperature, and oxygen exposure. In a low-shear granulator, the API is pre-blended with pregelatinized starch and microcrystalline cellulose at 5.0–8.0 wt% API on dry mass; binder solution 5–8% w/w pregelatinized starch in purified water is added to a wet-mass endpoint of 18–22% LOD. The wet mass is passed through a 1.0–1.2 mm screen and dried in a fluid-bed dryer with inlet air temperature 40–45 °C until LOD is ≤2.5%; tray drying at 50 °C may be used only if the bed depth is kept below 2.0 cm and the drying time is not extended beyond 120 min, because oxygen exposure causes surface bleaching of beadlets and analytically visible total lutein loss. An antioxidant couple of 0.2–1.0 wt% ascorbyl palmitate and 0.1–0.5 wt% alpha-tocopherol is added by dry dispersion before granulation to suppress free-radical chain reactions at beadlet–water interfaces. Dried granules are milled through a 0.8 mm screen; the fraction between 125 µm and 710 µm is retained for capsule filling or tablet compression. In-process control uses USP <731> loss on drying, Ph. Eur. 2.9.36 powder flow, and USP <616> bulk/tapped density; finished-product assessment follows USP <711>, USP <905>, and ICH Q3B degradation products. The terminal product types are oval film-coated tablets or size 3 hard gelatin capsules delivering 20–30 mg lutein per unit, the higher dose being the principal justification for tolerating the aqueous process window.

Soft gelatin capsule filling of lutein ester oleoresin represents the most concentrated downstream format for marigold flower extract, as the lipophilic oleoresin can be directly dispersed into a vegetable oil–based fill matrix without aqueous granulation or beadlet conversion. For a 10 mg free-lutein dose, 50–63 mg of a 20% lutein ester oleoresin is dispersed in 250–350 mg of fill mass, placing the API addition at 16–20 wt% of the fill. Yellow beeswax is included at 2–4 wt% and sunflower lecithin at 1–2 wt% to maintain suspension homogeneity and yield stress sufficient to prevent phase separation during storage. The fill is sparged with nitrogen to dissolved oxygen below 4 ppm, and the blend is deaerated under 0.08 MPa vacuum for 30 min before encapsulation. Rotary die encapsulation is operated at 18–22 °C and 30–45% relative humidity; ribbon thickness is maintained at 0.9–1.1 mm, and seam thickness is checked at start, middle, and end of each batch. Compliance testing includes USP <711> dissolution with pepsin in simulated gastric fluid to address crosslinked gelatin, USP <905>, ICH Q3C residual solvents for the oil extraction train, and ICH Q3D for elemental impurities. The terminal product type is a soft gelatin capsule containing a translucent orange fill mass, packaged in amber glass or opaque polymer bottles. Production-scale experience with lutein oleoresin shows that batch-to-batch filling weight variance often originates from poor deaeration rather than pump calibration; a vacuum leak test and mass flow check are therefore critical in-process controls.

Fluid-Bed Granulation Parameters for Water-Dispersible Lutein Beadlet Systems

Water-dispersible beadlet grades of marigold flower extract are designed for fluid-bed granulation into sachet or suspension powders, where the API is already embedded in a starch or maltodextrin matrix to reduce oxygen and light sensitivity. The API beadlet is loaded at 10–30 wt% of the dry granule mass; the binder solution contains 6–8% w/w maltodextrin or polyvinylpyrrolidone K30, sprayed at 8–12 g/min per kg of batch in a top-spray fluid-bed granulator. Inlet air is set at 45–55 °C, product temperature is held at 30–38 °C, atomizing air pressure is 1.5–2.5 bar, and the 1.2 mm two-fluid nozzle is positioned to prevent overwetting of the filter bag. Spray rate is reduced if the bed humidity exceeds 35%; otherwise the beadlet matrix becomes tacky and builds up on the product filter, a batch-stopping failure observed on production-scale top-spray units. Granulation proceeds to a moisture endpoint of 2.0–3.5% LOD, followed by screening through a 0.8 mm sieve and a final blend with 0.3–0.8 wt% hydrophobic fumed silica to restore flow. Powder flow is evaluated by Ph. Eur. 2.9.36; particle-size distribution is checked by laser diffraction; sachet fill weight control follows USP <905>. Finished products comply with USP <711> if the granules are formulated as an oral suspension, ICH Q3D elemental impurities, and ICH Q3B degradation products. The terminal product type is a unit-dose granule sachet for reconstitution in water, or a bulk powder for pediatric and geriatric oral administration.

An injectable submicron oil-in-water emulsion containing marigold flower extract remains an experimental ophthalmic or parenteral-nutrition carrier because lutein/zeaxanthin aqueous solubility is negligible, requiring a lipid oil phase that must remain below the pharmacopeial globule-size threshold after sterilization. Published experimental formulations place lutein loading at 0.05–0.30 mg/mL of finished emulsion; the oil phase is 5–20 wt% composed of medium-chain triglyceride/long-chain triglyceride mixture, with phospholipid emulsifier at 1.2–1.8 wt% and glycerol at 2.25–2.5 wt% for isotonicity. The API is dissolved in the oil phase at 60–70 °C under nitrogen, then a coarse emulsion is formed by rotor-stator high shear at 10,000–15,000 rpm for 5–10 min. Homogenization is performed on a high-pressure homogenizer at 500–1,000 bar for 5–8 passes; the product is cooled to 20–25 °C between passes to avoid coalescence, then adjusted to pH 7.0–7.8 and filtered through a 0.22 µm terminal filter under aseptic conditions. Compliance testing is performed against USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter, and USP <729> globule size distribution, with mean droplet diameter <500 nm and the >5 µm particulate fraction ≤0.05%; elemental impurities follow ICH Q3D. The terminal product type is a sterile injectable emulsion in 5 mL or 10 mL amber vials. Published data for commercial injectable marigold flower extract is limited; the operating values above are drawn from experimental ophthalmic lipid emulsions and are not automatically transferable to a licensed finished pharmaceutical.

When Direct-Compression Blends Are Replaced by Dry-Granulated Roller-Compacted Granules

Where high-dose tablets exceed the practical API load of direct compression, roller compaction avoids aqueous granulation by densifying the marigold extract blend into ribbons, followed by milling into granules. The formulation places the API at 5.0–12.0 wt% of dry granulate mass, microcrystalline cellulose at 30–50 wt%, crospovidone or croscarmellose sodium at 3–5 wt%, and magnesium stearate at 0.5–1.0 wt%; a portion of the lubricant is withheld from the compaction step and added in a final blending step to preserve tablet compactibility. Roll compaction is run at roll pressure 30–80 kN, roll speed 3–8 rpm, and gap 1.5–3.0 mm on a 10 cm ribbed roll surface. The ribbons are milled through a 0.8–1.25 mm rotor screen; granules below 150 µm are recycled to the compactor at 20–30% of feed, while granules above 850 µm are re-milled. Dry granulation produces a more uniform particle-size distribution than direct compression, but the compaction force must be controlled because beadlet fracture accelerates lutein oxidation; if the fine fraction below 150 µm exceeds 25%, content uniformity and flow decline. In-process controls include USP <616> bulk and tapped density, Ph. Eur. 2.9.36 powder flow, and USP <905> uniformity of dosage units; finished-product release uses USP <711> dissolution and ICH Q3B degradation products. The terminal dosage forms are tablets or hard capsules delivering 20–40 mg lutein per unit, in which the higher API mass renders direct compression impractical.